BioCentury | Aug 18, 2011
Distillery Techniques

Technology: Imaging

...doi:10.1038/scibx.2011.921 Published online Aug. 18, 2011 Patented by the University of California, Irvine; licensed to Spectros...
BioCentury | Jun 4, 2007
Tools & Techniques

Signal snapshots

Mass spectrometry-based proteomics can reveal protein-protein interactions using large sample sizes and analyzing binding relationships long after a cell signal has started. But it has been difficult to parse the molecular events as they occur...
BioCentury | May 22, 2000
Company News

Draxis, Block Drug Co. Inc. deal

BLOCA's Block Drug Co. (Canada) Ltd. subsidiary will purchase DRAX's Spectro line of OTC dermatology products for C$12.5 million (US$8.5 million). Draxis Health Inc. (TSE:DAX; DRAX), Mississauga, Ontario Block Drug Co. Inc. (BLOCA), Jersey City,...
BioCentury | May 8, 2000
Company News

Draxis, Block Drug Co. Inc. deal

BLOCA's Block Drug Co. (Canada) Ltd. subsidiary will purchase DRAX's Spectro line of over-the-counter dermatology products for C$12.5 million (US$8.5 million). DRAX said annual revenues for the product line are C$5 million. The agreement includes...
Items per page:
1 - 4 of 4
BioCentury | Aug 18, 2011
Distillery Techniques

Technology: Imaging

...doi:10.1038/scibx.2011.921 Published online Aug. 18, 2011 Patented by the University of California, Irvine; licensed to Spectros...
BioCentury | Jun 4, 2007
Tools & Techniques

Signal snapshots

Mass spectrometry-based proteomics can reveal protein-protein interactions using large sample sizes and analyzing binding relationships long after a cell signal has started. But it has been difficult to parse the molecular events as they occur...
BioCentury | May 22, 2000
Company News

Draxis, Block Drug Co. Inc. deal

BLOCA's Block Drug Co. (Canada) Ltd. subsidiary will purchase DRAX's Spectro line of OTC dermatology products for C$12.5 million (US$8.5 million). Draxis Health Inc. (TSE:DAX; DRAX), Mississauga, Ontario Block Drug Co. Inc. (BLOCA), Jersey City,...
BioCentury | May 8, 2000
Company News

Draxis, Block Drug Co. Inc. deal

BLOCA's Block Drug Co. (Canada) Ltd. subsidiary will purchase DRAX's Spectro line of over-the-counter dermatology products for C$12.5 million (US$8.5 million). DRAX said annual revenues for the product line are C$5 million. The agreement includes...
Items per page:
1 - 4 of 4